<DOC>
	<DOCNO>NCT00707356</DOCNO>
	<brief_summary>The aim clinical study determine optimal treatment condition achieve prostate cancer tumor ablation ass effect WST11 mediate VTP treatment patient localized prostate cancer . The secondary objective evaluate safety quality life ; ass pharmacokinetic parameter model relationship concentration effect ; assess effect , safety quality life second WST11 VTP treatment patient persistent recurrent localize prostate cancer first VTP ;</brief_summary>
	<brief_title>Study WST11 Patients With Localized Prostate Cancer</brief_title>
	<detailed_description>This trial design multicentre , phase II , open-labeled , single intra-venous ( IV ) dose study . The patient receive general anesthesia . WST11-mediated VTP consist combination single IV administration WST11 dose 2 mg/Kg,4mg/Kg 6 mg/kg , use 753 nm laser light fixed power ( 150mW/cm ) energy ( 200 J/cm ) deliver transperineal interstitial optical fiber . If deem necessary consideration result patient treat 200 J/cm , alternate power ( 200mW/cm ) alternate energy ( 300 J/cm ) might apply Sponsor , Steering Committee DSMB approval.The fiber introduce transparent needle position prostate ultra sound image guidance ( use brachytherapy like template ) . The tumor location establish use transrectal biopsy MR imaging . The number fiber total light energy adapt patient , take account tumor localization volume prostate .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Diagnosed prostate cancer eligible active surveillance ; No prior treatment prostate cancer ; Prostate Cancer Stage cT2b N0/Nx M0/Mx ( rT2c pT2c acceptable ) ; Gleason score â‰¤ 3+3 For patient characterized prostate mapping ( transperineal template guide biopsy 5mm interval ) secondary pattern 4 acceptable provide present 3 core side prostate 3 mm cancer core length . PSA &lt; 10 ng/mL ; Any condition history illness surgery , opinion investigator and/or Sponsor , might confound result study pose additional risk patient . Patients prior history viral alcoholic hepatitis , patient felt risk hepatotoxicity include concomitant use potentially hepatotoxic medication dietary supplement ; History non compliance medical therapy medical recommendation unwillingness inability complete patient selfadministered questionnaire ; Participation clinical study receipt investigational treatment within past 3 month ; A history porphyria ; Patient contraindication MRI ( pace maker , metal prosthesis , etc . ) ; All patient whose current preoperative cardiac evaluation show fitness procedure require general anesthesia ; Patients history inflammatory bowel disease factor may increase risk fistula formation ; Men receive hormonal manipulation ( exclude 5alpha reductase inhibitor ) androgen supplement within previous 6 month ; Men previously treat radiation therapy ( external therapy brachytherapy ) chemotherapy therapy prostate cancer ; Men receive receive chemotherapy prostate carcinoma significant cancer ; Men undergo previous TURP ( transurethral resection prostate ) ; Men currently receive medication potential photosensitizing effect ( e.g . tetracycline , sulfonamide , phenothiazine , sulfonylurea hypoglycemic agent , thiazide diuretic griseofulvin ) ; Men receive anticoagulant drug ( e.g . : coumadin , warfarin ) Patient stop long term treatment acetylsalicylic acid ( aspirin ) anti platelets agent le 15 day procedure ; Patient suspect Disseminated Intravascular Coagulation ( DIC ) define presence three five follow criterion : platelet &lt; LLN , PT &gt; ULN , aPTT &gt; ULN , fibrinogen &lt; LLN , DDimer &gt; ULN ; A history sun hypersensitivity photosensitive dermatitis ; Renal disorder ( blood creatinine &gt; 1.5 x ULN ) know post mictional residue &gt; 150cc ; Hepatic disorder ( transaminase &gt; ULN , bilirubin &gt; ULN ) . In case slight abnormality , another exam perform . If result within normal range , patient include ; Hematological disorder ( white cell &lt; 2500/mm3 , neutrophil &lt; 1500/mm3 , platelet &lt; 140.000/mm3 , Hb &lt; 8 g/dl ) ;</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Prostatic disease</keyword>
	<keyword>genital neoplasm , male</keyword>
	<keyword>Urogenital neoplasm</keyword>
	<keyword>Genital disease</keyword>
	<keyword>male</keyword>
	<keyword>Male urogenital disease</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Neoplasm site</keyword>
	<keyword>prostatic neoplasm</keyword>
	<keyword>Carcinoma</keyword>
</DOC>